This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Thermo Fisher Scientific is a scientific instrument maker and a world leader in serving science. In Nov 2006, Thermo Fisher Scientific, Inc. was formed through the merger of Thermo Electron Corporation with Fisher Scientific International Inc. On Feb 3, 2014, Thermo Fisher acquired Life Technologies Corporation. Following the acquisition, the new reporting segments are: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
PerkinElmer (PKI) Q3 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
PerkinElmer's (PKI) Q3 earnings benefits from higher revenues and growth in DAS and Diagnostics segments. However, forex remains a woe.
ABIOMED (ABMD) Earnings Beat, Revenues Miss Estimates in Q2
by Zacks Equity Research
Impella's solid show in Japan drives ABIOMED's (ABMD) fiscal second-quarter results.
QIAGEN (QGEN) Beats Q3 Earnings Estimates, Cuts Revenue View
by Zacks Equity Research
We are impressed with QIAGEN's (QGEN) year-over-year growth across majority of operating segments in Q3.
Masimo (MASI) Earnings Beat Estimates in Q3, View Raised
by Zacks Equity Research
Masimo (MASI) raises its 2019 product revenue guidance.
Impressive Near-Term Outlook for Medical Instruments Industry
by Urmimala Biswas
Growing medical awareness and economic prosperity enhance the uptake of medical instruments in the emerging economies.
Chemed (CHE) Q3 Earnings Surpass Estimates, Revenues Miss
by Zacks Equity Research
Chemed (CHE) witnesses balanced segmental growth in third-quarter 2019.
McKesson (MCK) Q2 Earnings Meet Estimates, Revenues Beat
by Zacks Equity Research
McKesson's (MCK) Q2 results gain from higher revenues and solid show by U.S. Pharmaceutical and Specialty, and Medical-Surgical Solutions.
Fresenius Medical (FMS) Q3 Earnings & Revenues Top Estimates
by Zacks Equity Research
Fresenius Medical's (FMS) Q3 earnings benefit from strong segmental performance and solid 2019 EPS outlook.
Stryker (SYK) Q3 Earnings Meet Estimates, Revenues Beat
by Zacks Equity Research
Stryker's (SYK) Q3 earnings gain from higher revenues, solid segmental performance and strong organic growth across businesses benefit.
Cardiovascular Systems (CSII) Loss Wider Than Estimates in Q1
by Zacks Equity Research
We are upbeat about the year-over-year uptick in both Coronary and peripheral device revenues within Cardiovascular Systems' (CSII) domestic market.
Accuray (ARAY) Q1 Wider Than Expected, FY20 View Retained
by Zacks Equity Research
Accuray (ARAY) reiterates revenue and adjusted EBITDA view for fiscal 2020.
Ecolab (ECL) Earnings and Revenues Miss Estimates in Q3
by Zacks Equity Research
Global Industrial unit aid Ecolab's (ECL) Q3 results; 2019 EPS view slashed.
Has Thermo Fisher Scientific (TMO) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (TMO) Outperforming Other Medical Stocks This Year?
Walgreens Boots (WBA) Q4 Earnings Surpass, Margins Fall
by Zacks Equity Research
Growth within the Retail Pharmacy USA and Pharmaceutical Wholesale divisions of Walgreens Boots (WBA) is partially offset by a dull performance at Retail Pharmacy International.
Omnicell (OMCL) Beats on Q3 Earnings, Raises '19 EPS View
by Zacks Equity Research
Omnicell (OMCL) continues to see solid segmental contributions in Q3. Expansion of gross and operating margins is a positive too.
Cerner (CERN) Earnings Beat Estimates in Q3, Improve Y/Y
by Zacks Equity Research
Cerner (CERN) Q3 results benefit from higher revenues, gains in Licensed software, Technology resale, Professional and Managed services units, and international revenue growth.
NextGen (NXGN) Q2 Earnings Beat, Revenues Miss Estimates
by Zacks Equity Research
NextGen (NXGN) retains its fiscal 2020 revenue and EPS guidance.
GNC Holdings (GNC) Q3 Loss Meets Estimates, Revenues Miss
by Zacks Equity Research
GNC Holdings' (GNC) third-quarter 2019 results, reflecting dismal performance across segments, disappoint investors.
TMO vs. EW: Which Stock Is the Better Value Option?
by Zacks Equity Research
TMO vs. EW: Which Stock Is the Better Value Option?
Illumina (ILMN) Beats Q3 Earnings Estimates, Raises View
by Zacks Equity Research
Illumina (ILMN) announces impressive Q3 results on the back of strong growth in the sequencing business.
Company News For Oct 24, 2019
by Zacks Equity Research
Companies In The News Are: ALXN,ANTM,TMO,BSX
Thermo Fisher (TMO) Beats on Q3 Earnings, Lifts Guidance
by Zacks Equity Research
We are encouraged that three out of Thermo Fisher's (TMO) four business segments have registered strong year-over-year revenue growth in Q3.
Thermo Fisher Scientific (TMO) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Thermo Fisher (TMO) delivered earnings and revenue surprises of 2.08% and 1.33%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Medical Products' Earnings Roster for Oct 23: TMO, BSX & More
by Zacks Equity Research
Encouraging growth in the emerging markets despite the ongoing trade tiff is likely to contribute to revenues in the medical products space this earnings season.
What's in Store for Thermo Fisher (TMO) in Q3 Earnings?
by Zacks Equity Research
Developments in business segments are likely to have aided Thermo Fisher (TMO) in the third quarter.